BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

23 related articles for article (PubMed ID: 8141112)

  • 1. Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study.
    Oliva C; Bergnolo P; Inguì M; Bianco L; Pochettino P; Cutin SC; Boglione A; Dal Canton O; Garetto F; Comandone A
    J Cancer Res Clin Oncol; 2010 Mar; 136(3):411-7. PubMed ID: 19727815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin.
    Margolin KA; Doroshow JH; Akman SA; Leong LA; Morgan RJ; Raschko JW; Somlo G; Blevins C
    J Clin Oncol; 1992 Aug; 10(8):1278-83. PubMed ID: 1634917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
    Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
    Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U; Wilke H; Seeber S
    J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging role of 5-fluorouracil and leucovorin in the treatment of advanced breast cancer. A review.
    Zaniboni A
    J Chemother; 1989 Oct; 1(5):330-7. PubMed ID: 2685188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid.
    Mini E; Trave F; Rustum YM; Bertino JR
    Pharmacol Ther; 1990; 47(1):1-19. PubMed ID: 2195551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of 5-fluorouracil and high-dose folinic acid as first- or second-line therapy for advanced breast cancer.
    Margolin KA; Green S; Osborne K; Doroshow JH; Akman SA; Leong LA; Morgan RJ; Raschko JW; Somlo G; Hutchins L
    Am J Clin Oncol; 1994 Apr; 17(2):175-80. PubMed ID: 8141112
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.